Fig. 2: Effects of PACE-PEG dosing on blood concentration and biodistribution. | Nature Communications

Fig. 2: Effects of PACE-PEG dosing on blood concentration and biodistribution.

From: Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys

Fig. 2

a Blood NP concentration over time following systemic IV injection of dye-loaded PACE-PEG NPs at various doses (0.1 mg: pink, 0.5 mg: orange, 2.0 mg: green, 2.5 mg: turquoise, and 3.5 mg: indigo per animal corresponding to approximately 30 billion, 160 billion, 650 billion, 800 billion, and 1 trillion NPs, respectively) using quantitative microscopy (n = 3 mice per group per time point; error bars represent standard deviation (SD)). b Circulation half-life of PACE-PEG NPs as a function of dose. Representative end-point (c) IVIS analysis of PACE-PEG NP uptake in various organs (heart, lungs, liver, spleen, kidneys, and bone), CTL: untreated control. End-point analysis of (d) whole organ fluorescence quantification of PACE-PEG NP uptake in various organs (n = 3 mice per group per organ; error bars represent SD). End-point analyses of (e) %NP+ cells and (f) Mean fluorescence intensity (MFI) in arbitrary units (arb. units) of homogenized organs by flow cytometry (n = 3 mice per group per organ; error bars represent SD). End-point analysis of (g) %NP+ cells and (h) MFI in homogenized liver populations (bulk, F4/80+, and CD31+) by flow cytometry (n = 3 mice per group per population; error bars represent SD). End-point analyses of (i) %NP+ cells and (j) MFI in homogenized lung populations (bulk, CD45+, and EpCAM+) by flow cytometry (n = 3 mice per group per population; error bars represent SD). k End-point analyses of %NP + F4/80− cells in the liver as a function of dose (n = 3 mice per dose; error bars represent SD). l End-point analysis of the ratio of %NP + F4/80− cells to %NP + F4/80+ cells in the liver as a function of dose (n = 3 mice per dose; error bars represent SD).

Back to article page